{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T21:12:08Z","timestamp":1787605928260,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In this meta-analysis, we aimed to estimate and compare the efficacy of add-on treatment of antidepressants with esketamine nasal spray and second-generation antipsychotics in patients with nonpsychotic major depressive disorder and inadequate response to antidepressants. Searching for acute-phase, double-blind, placebo-controlled, randomized trials, we found 22 second-generation antipsychotic (n\u2009=\u20098363) and 3 intranasal esketamine (n\u2009=\u2009641) studies. Mean change in the Montgomery \u00c5sberg Depression Rating Scale total score served as outcome. We determined a higher mean difference (vs placebo) for the pooled esketamine nasal spray trials (mean difference\u2009=\u20094.09, 95% confidence interval: 2.01 to 6.17) than for the pooled second-generation antipsychotic augmentation trials (mean difference \u2009=\u20092.05, 95% confidence interval: 1.51 to 2.59). Thus, the effect size for intranasal esketamine was nearly twice as high as those for the second-generation antipsychotics. This indicates high efficacy of add-on esketamine nasal spray in treatment-resistant major depressive disorder compared with other well-established, evidence-based pharmacological options such as augmentation with second-generation antipsychotics.<\/jats:p>","DOI":"10.1093\/ijnp\/pyaa034","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T11:26:52Z","timestamp":1589801212000},"page":"440-445","source":"Crossref","is-referenced-by-count":33,"title":["Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment"],"prefix":"10.1093","volume":"23","author":[{"given":"Markus","family":"Dold","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Bartova","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"2020072901470404300_CIT0001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice","volume":"20","author":"Bartova","year":"2019","journal-title":"World J Biol Psychiatry"},{"key":"2020072901470404300_CIT0002","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/13651501.2017.1306082","article-title":"Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines","volume":"21","author":"Bauer","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2020072901470404300_CIT0003","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1017\/S1461145713000400","article-title":"Rational site-directed pharmacotherapy for major depressive disorder","volume":"17","author":"Blier","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"2020072901470404300_CIT0004","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.euroneuro.2018.10.003","article-title":"Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - results from a European multicenter study","volume":"28","author":"Dold","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"2020072901470404300_CIT0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13651501.2016.1248852","article-title":"Evidence-based pharmacotherapy of treatment-resistant unipolar depression","volume":"21","author":"Dold","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2020072901470404300_CIT0006","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.euroneuro.2016.10.005","article-title":"Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - a pharmacoepidemiological cross-sectional multicenter study","volume":"26","author":"Dold","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"2020072901470404300_CIT0007","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: a study in 16 countries, 2005-2014","volume":"27","author":"Halfdanarson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"2020072901470404300_CIT0008","author":"Higgins","year":"2019","edition":"eds"},{"key":"2020072901470404300_CIT0009","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/wps.20245","article-title":"Factors contributing to the increasing placebo response in antidepressant trials","volume":"14","author":"Kasper","year":"2015","journal-title":"World Psychiatry"},{"key":"2020072901470404300_CIT0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S1461145711000745","article-title":"Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program","volume":"15","author":"Konstantinidis","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"2020072901470404300_CIT0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13651501.2016.1254802","article-title":"Administration of ketamine for unipolar and bipolar depression","volume":"21","author":"Kraus","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2020072901470404300_CIT0012","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"key":"2020072901470404300_CIT0013","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2020072901470404300_CIT0014","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","article-title":"Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"2020072901470404300_CIT0015","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"2020072901470404300_CIT0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"2020072901470404300_CIT0017","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.biopsych.2007.08.010","article-title":"Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches","volume":"63","author":"Papakostas","year":"2008","journal-title":"Biol Psychiatry"},{"key":"2020072901470404300_CIT0018","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A model of placebo response in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2020072901470404300_CIT0019","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4088\/JCP.08r04516blu","article-title":"Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses","volume":"71","author":"Sinyor","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"2020072901470404300_CIT0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JCP.0b013e3182228619","article-title":"Switching antidepressant class does not improve response or remission in treatment-resistant depression","volume":"31","author":"Souery","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"2020072901470404300_CIT0021","doi-asserted-by":"crossref","first-page":"pyv060","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis","volume":"25","author":"Zhou","year":"2015","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaa034\/33416373\/pyaa034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/7\/440\/33540999\/pyaa034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/7\/440\/33540999\/pyaa034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T05:47:26Z","timestamp":1596001646000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/23\/7\/440\/5860938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaa034","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,6,22]]}}}